Loading…
Berberine: A potential adjunct for the treatment of gastrointestinal cancers?
Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. B...
Saved in:
Published in: | Journal of cellular biochemistry 2018-12, Vol.119 (12), p.9655-9663 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303 |
---|---|
cites | cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303 |
container_end_page | 9663 |
container_issue | 12 |
container_start_page | 9655 |
container_title | Journal of cellular biochemistry |
container_volume | 119 |
creator | Hesari, AmirReza Ghasemi, Faezeh Cicero, Arrigo F. G. Mohajeri, Mohammad Rezaei, Omid Hayat, Seyed Mohammad Gheibi Sahebkar, Amirhossein |
description | Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers.
This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects. |
doi_str_mv | 10.1002/jcb.27392 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2091235408</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2129471086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</originalsourceid><addsrcrecordid>eNp10DtPwzAUBWALgWgpDPwBFIkFhrTXjyYxC2ornipigTmyHRtS5VFsR6j_HtMUBiSmO9xPR0cHoVMMYwxAJislxySlnOyhIQaexixhbB8NIaUQE4rJAB05twIAzik5RAMKmEx5yoboaa6t1LZs9FU0i9at140vRRWJYtU1ykemtZF_15G3Wvg6PKPWRG_CeduWjdfOl03QSjRKW3d9jA6MqJw-2d0Rer29eVncx8vnu4fFbBkrOqUk5iAZhAoaRCJNwYWUkGVGTgEoo1olPJHc0O0Lq1QpbowShBYsBawo0BG66HPXtv3oQou8Lp3SVSUa3XYuJ8AxoVMGWaDnf-iq7WwoHRQmnKUYsiSoy14p2zpntcnXtqyF3eQY8u-N87Bxvt042LNdYidrXfzKn1EDmPTgs6z05v-k_HEx7yO_ABazhOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2129471086</pqid></control><display><type>article</type><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><source>Wiley</source><creator>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</creator><creatorcontrib>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</creatorcontrib><description>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers.
This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</description><identifier>ISSN: 0730-2312</identifier><identifier>EISSN: 1097-4644</identifier><identifier>DOI: 10.1002/jcb.27392</identifier><identifier>PMID: 30125974</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acetyltransferase ; Apoptosis ; Berberine ; cancer ; Cyclin-dependent kinase inhibitor p27 ; DIABLO protein ; ErbB-2 protein ; Gastric cancer ; gastrointestinal tract ; Glioblastoma ; Hepatoma ; Immunomodulation ; Liver cancer ; Melanoma ; miRNA ; Oral carcinoma ; p53 Protein ; Pharmacology ; Prostate cancer ; Tumor cells ; Vascular endothelial growth factor</subject><ispartof>Journal of cellular biochemistry, 2018-12, Vol.119 (12), p.9655-9663</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</citedby><cites>FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</cites><orcidid>0000-0002-8656-1444</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30125974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hesari, AmirReza</creatorcontrib><creatorcontrib>Ghasemi, Faezeh</creatorcontrib><creatorcontrib>Cicero, Arrigo F. G.</creatorcontrib><creatorcontrib>Mohajeri, Mohammad</creatorcontrib><creatorcontrib>Rezaei, Omid</creatorcontrib><creatorcontrib>Hayat, Seyed Mohammad Gheibi</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><title>Journal of cellular biochemistry</title><addtitle>J Cell Biochem</addtitle><description>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers.
This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</description><subject>Acetyltransferase</subject><subject>Apoptosis</subject><subject>Berberine</subject><subject>cancer</subject><subject>Cyclin-dependent kinase inhibitor p27</subject><subject>DIABLO protein</subject><subject>ErbB-2 protein</subject><subject>Gastric cancer</subject><subject>gastrointestinal tract</subject><subject>Glioblastoma</subject><subject>Hepatoma</subject><subject>Immunomodulation</subject><subject>Liver cancer</subject><subject>Melanoma</subject><subject>miRNA</subject><subject>Oral carcinoma</subject><subject>p53 Protein</subject><subject>Pharmacology</subject><subject>Prostate cancer</subject><subject>Tumor cells</subject><subject>Vascular endothelial growth factor</subject><issn>0730-2312</issn><issn>1097-4644</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp10DtPwzAUBWALgWgpDPwBFIkFhrTXjyYxC2ornipigTmyHRtS5VFsR6j_HtMUBiSmO9xPR0cHoVMMYwxAJislxySlnOyhIQaexixhbB8NIaUQE4rJAB05twIAzik5RAMKmEx5yoboaa6t1LZs9FU0i9at140vRRWJYtU1ykemtZF_15G3Wvg6PKPWRG_CeduWjdfOl03QSjRKW3d9jA6MqJw-2d0Rer29eVncx8vnu4fFbBkrOqUk5iAZhAoaRCJNwYWUkGVGTgEoo1olPJHc0O0Lq1QpbowShBYsBawo0BG66HPXtv3oQou8Lp3SVSUa3XYuJ8AxoVMGWaDnf-iq7WwoHRQmnKUYsiSoy14p2zpntcnXtqyF3eQY8u-N87Bxvt042LNdYidrXfzKn1EDmPTgs6z05v-k_HEx7yO_ABazhOg</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Hesari, AmirReza</creator><creator>Ghasemi, Faezeh</creator><creator>Cicero, Arrigo F. G.</creator><creator>Mohajeri, Mohammad</creator><creator>Rezaei, Omid</creator><creator>Hayat, Seyed Mohammad Gheibi</creator><creator>Sahebkar, Amirhossein</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid></search><sort><creationdate>201812</creationdate><title>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</title><author>Hesari, AmirReza ; Ghasemi, Faezeh ; Cicero, Arrigo F. G. ; Mohajeri, Mohammad ; Rezaei, Omid ; Hayat, Seyed Mohammad Gheibi ; Sahebkar, Amirhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acetyltransferase</topic><topic>Apoptosis</topic><topic>Berberine</topic><topic>cancer</topic><topic>Cyclin-dependent kinase inhibitor p27</topic><topic>DIABLO protein</topic><topic>ErbB-2 protein</topic><topic>Gastric cancer</topic><topic>gastrointestinal tract</topic><topic>Glioblastoma</topic><topic>Hepatoma</topic><topic>Immunomodulation</topic><topic>Liver cancer</topic><topic>Melanoma</topic><topic>miRNA</topic><topic>Oral carcinoma</topic><topic>p53 Protein</topic><topic>Pharmacology</topic><topic>Prostate cancer</topic><topic>Tumor cells</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hesari, AmirReza</creatorcontrib><creatorcontrib>Ghasemi, Faezeh</creatorcontrib><creatorcontrib>Cicero, Arrigo F. G.</creatorcontrib><creatorcontrib>Mohajeri, Mohammad</creatorcontrib><creatorcontrib>Rezaei, Omid</creatorcontrib><creatorcontrib>Hayat, Seyed Mohammad Gheibi</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hesari, AmirReza</au><au>Ghasemi, Faezeh</au><au>Cicero, Arrigo F. G.</au><au>Mohajeri, Mohammad</au><au>Rezaei, Omid</au><au>Hayat, Seyed Mohammad Gheibi</au><au>Sahebkar, Amirhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Berberine: A potential adjunct for the treatment of gastrointestinal cancers?</atitle><jtitle>Journal of cellular biochemistry</jtitle><addtitle>J Cell Biochem</addtitle><date>2018-12</date><risdate>2018</risdate><volume>119</volume><issue>12</issue><spage>9655</spage><epage>9663</epage><pages>9655-9663</pages><issn>0730-2312</issn><eissn>1097-4644</eissn><abstract>Gastrointestinal cancers are among the most prevalent cancers in the general population. Despite effective early diagnostics and intervention, the gastrointestinal cancer‐related mortality still remains elevated. Berberine (BBR) is a benzyl tetra isoquinoline alkaloid exracted from several plants. BBR is nontoxic to human normal cells, but suppresses the growth of different tumor cells: melanoma, epidermoid carcinoma, hepatoma, oral carcinoma, glioblastoma, prostatic carcinoma, and gastric carcinoma. In particular, BBR seems to suppress the proliferation of gastrointestinal cancers in a number of preclinical models. Several mechanisms of action have been hypothesized and demonstrated: immunomodulation, inhibition of topoisomerase enzymes, suppression of the EGF receptor, Her2/neu, and the VEGF receptor, induction of p53, Cip1/p21, Kip1/p27, Rb expression, induction of apoptosis (by regulation of MMPs pathway, caspases, Bax, and Smac/DIABLO), inhibition of arylamin N‐acetyltransferase activity, and regulation of microRNAs expression. The aim of this review is to summarize the pharmacological effects of BBR on animal and human gastrointestinal cancers.
This review highlights the potential therapeutic role of berberine in gastrointestinal cancers. We have reviewed the molecular mechanisms of action of this alkaloid and the cellular targets through which berberine might exert its beneficial anti‐tumor effects.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30125974</pmid><doi>10.1002/jcb.27392</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0730-2312 |
ispartof | Journal of cellular biochemistry, 2018-12, Vol.119 (12), p.9655-9663 |
issn | 0730-2312 1097-4644 |
language | eng |
recordid | cdi_proquest_miscellaneous_2091235408 |
source | Wiley |
subjects | Acetyltransferase Apoptosis Berberine cancer Cyclin-dependent kinase inhibitor p27 DIABLO protein ErbB-2 protein Gastric cancer gastrointestinal tract Glioblastoma Hepatoma Immunomodulation Liver cancer Melanoma miRNA Oral carcinoma p53 Protein Pharmacology Prostate cancer Tumor cells Vascular endothelial growth factor |
title | Berberine: A potential adjunct for the treatment of gastrointestinal cancers? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A02%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Berberine:%20A%20potential%20adjunct%20for%20the%20treatment%20of%20gastrointestinal%20cancers?&rft.jtitle=Journal%20of%20cellular%20biochemistry&rft.au=Hesari,%20AmirReza&rft.date=2018-12&rft.volume=119&rft.issue=12&rft.spage=9655&rft.epage=9663&rft.pages=9655-9663&rft.issn=0730-2312&rft.eissn=1097-4644&rft_id=info:doi/10.1002/jcb.27392&rft_dat=%3Cproquest_cross%3E2129471086%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-90b40012e0a6bfd9abb088fb500343ec696b9f3bfd9a1c7cc9ffca23d4701c303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2129471086&rft_id=info:pmid/30125974&rfr_iscdi=true |